Status:
COMPLETED
A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Hepatitis C
Eligibility:
All Genders
20-64 years
Phase:
PHASE2
Brief Summary
The study evaluates safety and efficacy of vaniprevir (MK7009), when administered with Pegylated-Interferon (peg-IFN) and Ribavirin, in Japanese patients with Hepatitis C infection. The primary hypoth...
Eligibility Criteria
Inclusion
- Has chronic genotype 1 Hepatitis C infection
Exclusion
- Has not tolerated previous course of peg-IFN and ribavirin
- Has HIV
- Has Hepatitis B
- Has a history of clinically significant medical condition that may interfere with the study (e.g., stroke or chronic seizures or major neurological disorder) or is contraindicated for treatment with peg-IFN and ribavirin
Key Trial Info
Start Date :
April 20 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 23 2012
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00880763
Start Date
April 20 2009
End Date
February 23 2012
Last Update
October 9 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.